Sign in
Taking people in South KoreaNo phase

Wearable Heart Patch Checks for Hidden Atrial Fibrillation After Stroke

Tests a wearable heart patch to detect atrial fibrillation in people with unexplained stroke.

Key facts

Who runs it
Asan Medical Center
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause
Status
Recruiting
People taking part
100 people, planned
Started
28 Jan 2026
Expected to end
15 Feb 2029
Type of study
Interventional
Treatments tested
  • MEMO Patch M and MEMO Patch2
Record updated
6 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who had a stroke with no clear cause (ESUS) and need heart rhythm monitoring. A wearable ECG patch checks for atrial fibrillation that was not found before.

Age
19 years or older
Sex
All sexes can join.
Disease stage
Embolic stroke of undetermined source (ESUS), meaning a stroke whose cause was not found.

Main reasons for not taking part

  • Already diagnosed with atrial fibrillation or atrial flutter
  • A clearly identified cause of the stroke
  • Known allergy to adhesives or hydrogels
  • Cognitive vulnerability that makes it hard to understand the study and decide to join, in the investigator's judgment
  • Any other reason the principal investigator sees a risk in taking part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Participants may take part in this clinical study only if they meet all of the following criteria:
  • Adults aged 19 years or older who voluntarily provide written informed consent to participate in the study
  • Patients diagnosed with ESUS (Embolic Stroke of Undetermined Source)
  • Patients who require in-hospital or out-of-hospital electrocardiographic (ECG) monitoring

Who cannot take part

  • Individuals with a clearly identified cause of stroke
  • Individuals known to have allergic reactions to adhesives or hydrogels
  • Participants who meet any of the following criteria cannot be enrolled in this clinical study:
  • Individuals already diagnosed with atrial fibrillation or atrial flutter
  • Individuals who, in the investigator's judgment, have cognitive vulnerability that makes it difficult to understand the study information and voluntarily decide on participation
  • Any other individuals whom the principal investigator considers to be at potential risk by participating in the study or otherwise unsuitable for participation

Where in South Korea

  • Asan Medical CenterSeoul, South KoreaContact: Bum Joon Kim, MD, PhDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and safety of a wearable device in detecting previously undiagnosed atrial fibrillation through non-invasive long-term monitoring using a wearable single-lead ECG patch (MEMO Patch M, MEMO Patch2) in 100 patients with Embolic Stroke of Undetermined Source (ESUS) who require atrial fibrillation screening. Participants who meet all inclusion and exclusion criteria and provide written informed consent will wear the MEMO Patch M and undergo in-hospital telemetry monitoring using MEMO Cue for a minimum of 12 hours and up to 8 days. During hospitalization, 24-hour Holter monitoring will also be conducted. Before discharge, the investigator will review these results to determine whether implantable loop recorder (ILR) implantation is necessary. At the time of discharge, participants will wear MEMO Patch2 for up to 14 days for the first ECG monitoring period. One month after discharge, the investigator will review the results of the first monitoring and initiate the second ECG monitoring with MEMO Patch2. Three months after discharge, the results of the second ECG monitoring will be reviewed, and participation in the clinical trial will be completed.

The group in the trial

  • MEMO Patch Long-Term Monitoring(MEMO Patch M, MEMO Patch2)Treatment being tested

    Participants in this arm will undergo long-term ECG monitoring using MEMO Patch M during hospitalization and MEMO Patch2 after discharge. 24-hour Holter monitoring will also be performed, and ILR implantation will be assessed before discharge.

    Treatment: MEMO Patch M and MEMO Patch2

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Atrial Fibrillation Detection Using MEMO Patch in Patients With Stroke of Unknown Cause: A Single-Center, Prospective, Exploratory Trial to Validate the Efficacy and Safety of Noninvasive Long-Term Electrocardiographic Monitoring
Plain-language title
Wearable Heart Patch Checks for Hidden Atrial Fibrillation After StrokeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
6 February 2026